Top 20 of Carcinoma, Non-Small-Cell Lung

Article title # Publications/# Citations

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

2004: DWBell; BWBrannigan; DCChristiani; SGurubhagavatula; DAHaber; FGHaluska; PLHarris; SMHaserlat; ... DNLouis; TJLynch; RAOkimoto; JSettleman; RSordella; JGSupko;

1246

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

2004: TJBoggon; MJEck; YFujii; SGabriel; HGreulich; PHerman; PAJänne; BEJohnson; ... FJKaye; JCLee; NLindeman; MMeyerson; KNaoki; JGPaez; HSasaki; WRSellers; STracy;

1114

ras oncogenes in human cancer: a review.

1989: JLBos;

741

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

2007: LCCantley; FCappuzzo; JChristensen; JAEngelman; CMGale; AJHolmes; CHyland; PAJänne; ... BEJohnson; TKosaka; CLee; NLindeman; TMitsudomi; TMok; JOPark; AMRogers; YSong; KZejnullahu; XZhao;

646

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

2006: JBrahmer; ADowlati; RGray; DHJohnson; RLilenbaum; MCPerry; ASandler; JHSchiller;

646

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

2004: JDoherty; LFulton; RHeelan; MKris; DKupfer; EMardis; VMiller; WPao; ... KPoliti; VRusch; ISarkaria; BSingh; HVarmus; RWilson; MZakowski;

590

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

2009: AAArmour; BChewaskulyong; DTChu; ELDuffield; MFukuoka; BHan; YIchinose; HJiang; ... BMargono; TSMok; YNishiwaki; YOhe; NSaijo; PSunpaweravong; SThongprasert; CLWatkins; YLWu; CHYang; JJYang;

549

Erlotinib in previously treated non-small-cell lung cancer.

2005: National Cancer Institute of Canada Clinical Trials Group; ABezjak; DCampos; TCiuleanu; GClark; MDediu; BFindlay; VHirsh; ... DJohnston; SMaoleekoonpiroj; RMartins; JRodrigues Pereira; PSantabarbara; LSeymour; FAShepherd; MSmylie; EHTan; SThongprasert; DTu; Mvan Kooten;

536

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

2012: SAgrawal; RAAnders; SJAntonia; MBAtkins; JRBrahmer; RDCarvajal; LChen; CGDrake; ... SNGettinger; AGupta; FSHodi; LHorn; MJure-Kunkel; GDKollia; AJKorman; PDLeming; DFMcDermott; DMcDonald; TLMcMiller; DMPardoll; JDPowderly; WHSharfman; DCSmith; JASosman; DRSpigel; MSznol; JMTaube; SLTopalian; JMWigginton; HXu;

504

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

2005: MGKris; VAMiller; WPao; KAPoliti; GJRiely; RSomwar; HVarmus; MFZakowski;

484

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

2010: YJBang; DRCamidge; JGChristensen; JWClark; DBCosta; BJDezube; JAEngelman; PFidias; ... LGandhi; DAHaber; AJIafrate; PAJänne; WHKim; ELKwak; TJLynch; RGMaki; MMino-Kenudson; SHOu; MJRatain; RSalgia; LVSequist; JSettleman; GIShapiro; ATShaw; SMShreeve; BSolomon; HStubbs; WTan; MVarella-Garcia; GCWei; KWilner;

451

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

2005: TJBoggon; TDayaram; MJEck; BHalmos; PAJänne; BEJohnson; SKobayashi; OKocher; MMeyerson; DGTenen;

448

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

2007: HAburatani; MBando; YLChoi; MEnomoto; SFujiwara; HHatanaka; SIshikawa; YIshikawa; ... KKurashina; HMano; TNiki; SOhno; MSoda; YSohara; YSugiyama; STakada; HWatanabe; YYamashita;

440

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

2008: YBa; XCai; JChen; XChen; TGong; JGuo; XGuo; XJiang; ... QLi; RLi; XLi; LMa; GNing; XShang; JWang; JWang; KWang; WWang; YXiang; CXu; YYin; KZen; CYZhang; HZhang; JZhang; JZhang; YZhang; YZhang; PZheng;

430

Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

2004: HEndoh; THarano; HKonishi; TMitsudomi; MNagino; YNimura; HOsada; TTakahashi; ... JTakamizawa; STomida; KYanagisawa; YYatabe;

422

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

2002: Eastern Cooperative Oncology Group; CPBelani; DHarrington; DHJohnson; JKrook; CLanger; ASandler; JHSchiller; JZhu;

413

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

2007: CEBakalarski; MJComb; TLGu; AGuo; SPGygi; HHaack; YHu; JMKornhauser; ... KLee; DLi; YLi; JMacNeill; JMitchell; JNardone; RDPolakiewicz; APossemato; CReeves; JMRen; KRikova; JRush; BSmith; MStokes; LSullivan; ZTan; JVillén; RWetzel; JYu; JYuan; QZeng; XZhou;

370

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

2012: SAgrawal; SAlaparthy; SBhatia; JRBrahmer; LHCamacho; SChen; LQChow; CGDrake; ... KEaton; SMGoldberg; JFGrosso; AGupta; OHamid; PHwu; WJHwu; JKauh; AJKorman; RMartins; KOdunsi; DMPardoll; SMParker; HCPitot; TMSalay; SLTopalian; SSTykodi; JMWigginton;

358

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

2010: North-East Japan Study Group; MAndo; YFujita; AGemma; KHagiwara; MHarada; THarada; HHirano; ... AInoue; HIsobe; IKinoshita; KKobayashi; MMaemondo; HMiyazawa; SMorita; TNukiwa; TOgura; SOizumi; SOkinaga; YSaijo; SSugawara; TTanaka; KYoshimori; HYoshizawa;

329

Epidermal growth factor receptor mutations in lung cancer.

2007: DWBell; DAHaber; JSettleman; SVSharma;

318